COVID-19 Resources

Resources – If you have documents to add please:

• use the upload resource page https://www.bopa.org.uk/upload-a-resource
• or email digital@bopa.org.uk 

Useful Websites – If you have a useful website to add please:

• use the useful website submission pagehttps://www.bopa.org.uk/useful-websites/useful-websites-submissions/
• or email digital@bopa.org.uk 

UKCPA webinars:

These webinars are aimed at pharmacists who will be drafted into new areas of work during the COVID-19 crisis.

These webinars are FREE and open to all.  You can either watch them live and register via the RPS website OR watch the recorded sessions.  Recordings can be accessed from the below link on the RPS website or via our BOPA ‘Useful Websites’ link above:

https://www.rpharms.com/development/coronavirus-cpd-resources#critcarebasics

CRUK Your Treatment Diary Video for patients:

to help enable pre-treatment consultations to take place remotely to reduce the need for F2F consultations: https://youtu.be/16ZIZ3Il6UI

Articles from journals:

• COVID-19 in the Cancer Patient, Yeoh, C et al, Anesthesia & Analgesia: April 15, 2020 – Volume Publish Ahead of Print – Issue –
• The Impact of the COVID-19 Pandemic on Cancer Patients, (2020) Al-Quteimat, Osama; Amer, Amer Mustafa, American Journal of Clinical Oncology: April 16, 2020 – Volume Publish Ahead of Print – Issue – doi: 10.1097/COC.0000000000000712
• Caring for our cancer patients in the wake of COVID-19, (2020) Karim Hussien El-Shakankery K et al, British Journal of Cancer https://doi.org/10.1038/s41416-020-0843-5
• Managing COVID-19 in Patients With Cancer: A Double Blow for Oncologists (2020) Sahu et al, JCO Oncology Practice available at https://ascopubs.org/doi/full/10.1200/OP.20.00167

NHSE interim treatment options:

Message from Steve Williamson, NHS England Lead Cancer Pharmacist

29th April 2020 – NHSE Interim treatment options

Dear Colleague

You may have seen that NICE has published an updated table to the SACT clinical guideline NG161 listing many new Interim treatment options earlier this week. See https://www.nice.org.uk/guidance/ng161/resources/interim-treatment-change-options-during-the-covid19-pandemic-endorsed-by-nhs-england-pdf-8715724381. There are a couple of points of clarification for providers to note:

• Enzalutamide for prostate cancer states it is subject to confirmation, we can confirm enzalutamide is approved, and there is no need to check for confirmation. A Blueteq form for abiraterone for patients unable to tolerate enzalutamide will be made available in due course.
• Gilteritinib is approved for relapsed /refractory AML and not newly diagnosed AML.
• Nivolumab is approved in MSI-H colorectal cancer, the wording states ‘subject to confirmation’ we can confirm this is approved and there is no need to check for confirmation.
• A blueteq form for polatuzumab will be released in due course as NHSE is currently working with the company to ensure there is stock available for the selected patient group.

We advise all these indications are to be billed through the usual specialised commissioning route, as there is additional COVID19 funding available for them.  Any drugs where we have changed the CDF pathway are not funded through CDF as there is separate COVID19 funding for them. We are pleased to note that the manufacturers of many of these drugs have worked with NHS England and offered additional discounts to support the NHS during COVID19.

Password protected resources:

Please visit the forum area for members to see further resources for paid members only (third party resources).